Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

NCT02196506 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

837

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders

Interventions

DRUG: Placebo + ADT
DRUG: Brexpiprazole +ADT

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

[object Object]